NT-proBNP and circulating inflammation markers in prediction of a normal myocardial scintigraphy in patients with symptoms of coronary artery disease

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Rathcke, Camilla Noelle ^a   Kjøller, Erik ^a   Fogh Andersen, Niels ^a   Zerahn, Bo ^a   Vestergaard, Henrik ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GELATINASE B; INTERLEUKIN 6; UNCLASSIFIED DRUG; YKL 40 PROTEIN; BRAIN NATRIURETIC PEPTIDE; CHI3L1 PROTEIN, HUMAN; GLYCOPROTEIN; LECTIN; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MYOCARDIAL PERFUSION IMAGING; PREDICTION; PREDICTIVE VALIDITY; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SCREENING; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; AGED; BIOSYNTHESIS; ISCHEMIA; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; RISK;

AGED; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; FEMALE; GLYCOPROTEINS; HUMANS; INFLAMMATION; INTERLEUKIN-6; ISCHEMIA; LECTINS; MALE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; RISK; SEX FACTORS;

EID: 78649817451     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014196     Document Type: Article

References (42)

1. Clark AN, Beller GA (2005) The present role of nuclear cardiology in clinical practice. Q J Nucl Med Mol Imaging 49: 43-58.
2. Underwood SR, Anagnostopoulos C, Cerqueira M, Ell PJ, Flint EJ, et al. (2004) Myocardial perfusion scintigraphy: the evidence. Eur J Nucl Med Mol Imaging 31: 261-291.
3. Mowatt G, Vale L, Brazzelli M, Hernandez R, Murray A, et al. (2004) Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction. Health Technol Assess 8: iii-207.
4. Elhendy A, Schinkel AF, van Domburg RT, Bax JJ, Valkema R, et al. (2004) Prognostic value of stress Tc-99m tetrofosmin SPECT in patients with previous myocardial infarction: impact of scintigraphic extent of coronary artery disease. J Nucl Cardiol 11: 704-709.
5. Kroll D, Farah W, McKendall GR, Reinert SE, Johnson LL (2001) Prognostic value of stress-gated Tc-99m sestamibi SPECT after acute myocardial infarction. Am J Cardiol 87: 381-386.
6. Stratmann HG, Tamesis BR, Younis LT, Wittry MD, Miller DD (1994) Prognostic value of dipyridamole technetium-99m sestamibi myocardial tomography in patients with stable chest pain who are unable to exercise. Am J Cardiol 73: 647-652.
7. Berman DS, Hachamovitch R, Kiat H, Cohen I, Cabico JA, et al. (1995) Incremental value of prognostic testing in patients with known or suspected ischemic heart disease: a basis for optimal utilization of exercise technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. J Am Coll Cardiol 26: 639-647.
8. Zerahn B, Jensen BV, Nielsen KD, Moller S (2000) Increased prognostic value of combined myocardial perfusion imaging and exercise electrocardiography in patients with coronary artery disease. J Nucl Cardiol 7: 616-622.
9. Majstorov V, Pop GD, Vaskova O, Vavlukis M, Peovska I, et al. (2008) Creactive protein in patients with normal perfusion and mild to moderate perfusion defects who have undergone myocardial perfusion imaging with 99m- Tc sestamibi gated spect. Prilozi 29: 67-76.
10. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, et al. (2004) Creactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350: 1387-1397.
11. Blake GJ, Ridker PM (2002) Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 252: 283-294.
12. Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, et al. (2008) Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 5: e78.
13. de Lemos JA, McGuire DK, Drazner MH (2003) B-type natriuretic peptide in cardiovascular disease. Lancet 362: 316-322.
14. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R (2005) Nterminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 352: 666-675.
15. Weber M, Mitrovic V, Hamm C (2006) B-type natriuretic peptide and Nterminal pro-B-type natriuretic peptide - Diagnostic role in stable coronary artery disease. Exp Clin Cardiol 11: 99-101.
16. Rathcke CN, Vestergaard H (2009) YKL-40-an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol 8: 61.
17. Galis ZS, Sukhova GK, Kranzhofer R, Clark S, Libby P (1995) Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci U S A 92: 402-406.
18. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105: 1135-1143.
19. de NR, Verkleij CJ, von der Thusen JH, Jukema JW, van der Wall EE, et al. (2006) Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol 26: 340-346.
20. Kucur M, Isman FK, Karadag B, Vural VA, Tavsanoglu S (2007) Serum YKL- 40 levels in patients with coronary artery disease. Coron Artery Dis 18: 391-396.
21. Wang Y, Ripa RS, Johansen JS, Gabrielsen A, Steinbruchel DA, et al. (2008) YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scand Cardiovasc J 42: 295-302.
22. Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, et al. (2009) High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J 30: 1066-1072.
23. Nojgaard C, Host NB, Christensen IJ, Poulsen SH, Egstrup K, et al. (2008) Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis 19: 257-263.
24. Zeng B, Prasan A, Fung KC, Solanki V, Bruce D, et al. (2005) Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Intern Med J 35: 331-335.
25. Ferroni P, Basili S, Martini F, Cardarello CM, Ceci F, et al. (2003) Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. J Investig Med 51: 295-300.
26. Wingard DL, Suarez L, Barrett-Connor E (1983) The sex differential in mortality from all causes and ischemic heart disease. Am J Epidemiol 117: 165-172.
27. Kaushik M, Sontineni SP, Hunter C (2010) Cardiovascular disease and androgens: a review. Int J Cardiol 142: 8-14.
28. Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, et al. (2003) Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 17: 1105-1107.
29. D'Souza SP, Baxter GF (2003) B Type natriuretic peptide: a good omen in myocardial ischaemia? Heart 89: 707-709.
30. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, et al. (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350: 655-663.
31. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, et al. (2003) Nterminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 108: 275-281.
32. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, et al. (2001) The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345: 1014-1021.
33. Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD (2004) Nterminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 110: 3206-3212.
34. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, et al. (2008) Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 358: 2107-2116.
35. Peer A, Falkensammer G, Alber H, Kroiss A, Griesmacher A, et al. (2009) Limited utilities of N-terminal pro B-type natriuretic peptide and other newer risk markers compared with traditional risk factors for prediction of significant angiographic lesions in stable coronary artery disease. Heart 95: 297-303.
36. Johansen JS (2006) Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 53: 172-209.
37. Rathcke CN, Raymond I, Kistorp C, Hildebrandt P, Faber J, et al. (2010) Low grade inflammation as measured by levels of YKL-40: Association with an increased overall and cardiovascular mortality rate in an elderly population. Int J Cardiol 143: 35-42.
38. Rathcke CN, Persson F, Tarnow L, Rossing P, Vestergaard H (2009) YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care 32: 323-328.
39. Sukhija R, Fahdi I, Garza L, Fink L, Scott M, et al. (2007) Inflammatory markers, angiographic severity of coronary artery disease, and patient outcome. Am J Cardiol 99: 879-884.
40. Hlatky MA, Ashley E, Quertermous T, Boothroyd DB, Ridker P, et al. (2007) Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease. Am Heart J 154: 1043-1051.
41. Sharir T, Kang X, Germano G, Bax JJ, Shaw LJ, et al. (2006) Prognostic value of poststress left ventricular volume and ejection fraction by gated myocardial perfusion SPECT in women and men: gender-related differences in normal limits and outcomes. J Nucl Cardiol 13: 495-506.
42. Mercaldo ND, Lau KF, Zhou XH (2007) Confidence intervals for predictive values with an emphasis to case-control studies. Stat Med 26: 2170-2183.